← All Signals

🏥 FDA: The Harvard Drug Group LLC — Class II

healthcareactionableSource: FDA
75%Confidence
0Views
FDASource
2026-03-22Date

Summary

Harvard Drug Group's recall of Midodrine tablets due to defective blister packaging creates immediate supply concerns for this blood pressure medication. The packaging failure could lead to product degradation and efficacy issues, potentially affecting patient safety and requiring rapid replacement inventory.

Actionable: Immediately verify inventory of Midodrine Hydrochloride Tablets and source alternative suppliers to maintain patient access.

AI Confidence: 75%

Data Points

firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now